Cosmos Health (NASDAQ:COSM – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Other equities analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cosmos Health in a research note on Wednesday, October 28th. Noble Financial initiated coverage on Cosmos Health in a research report on Monday, October 26th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.
View Our Latest Stock Analysis on COSM
Cosmos Health Trading Down 22.0%
Shares of COSM opened at $3.24 on Friday. Cosmos Health has a one year low of $3.00 and a one year high of $15.40. The company has a current ratio of 1.05, a quick ratio of 0.92 and a debt-to-equity ratio of 0.15. The company’s fifty day moving average price is $6.06 and its 200 day moving average price is $5.98.
Cosmos Health (NASDAQ:COSM – Get Free Report) last released its earnings results on Tuesday, August 18th. The company reported ($2.00) earnings per share for the quarter, hitting analysts’ consensus estimates of ($2.00). Cosmos Health had a negative net margin of 33.08% and a negative return on equity of 56.88%. The firm had revenue of $19.32 million during the quarter, compared to analyst estimates of $18.99 million. Equities research analysts anticipate that Cosmos Health will post -0.15 earnings per share for the current year.
Institutional Investors Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Renaissance Technologies LLC increased its stake in shares of Cosmos Health Inc. (NASDAQ:COSM – Free Report) by 16.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 390,500 shares of the company’s stock after acquiring an additional 55,925 shares during the quarter. Renaissance Technologies LLC owned about 0.75% of Cosmos Health worth $124,000 at the end of the most recent reporting period. Institutional investors own 12.61% of the company’s stock.
About Cosmos Health
Cosmos Health Inc. is a healthcare group that develops, manufactures and distributes pharmaceutical, nutraceutical and healthcare products. Its portfolio includes branded dietary supplements, vitamins and wellness products, as well as pharmaceutical products and medical devices distributed through retail, wholesale and online channels. The company markets its nutraceutical products under the Sky Premium Life brand, which offers supplements and other health and wellness products. Cosmos Health also has manufacturing and product-development activities through Cana Laboratories, a Greece-based pharmaceutical manufacturer that produces pharmaceutical and healthcare products for its own portfolio and third parties.
Featured Articles
- Five stocks we like better than Cosmos Health
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
